Skip to main content

Table 2 Association results for phase II and pooled analysis

From: A colorectal cancer genome-wide association study in a Spanish cohort identifies two variants associated with colorectal cancer risk at 1p33 and 8p12

LOCUS

SNP

P PHASE II

OR (95% CI)

POOLED P

POOLED OR (95% CI)

1p33

rs12080929

0.042

0.867 (0.722-0.994)

5.523E-03

0.866 (0.782-0.959)

1p33

rs12080061*

0.087

0.870 (0.743-1.020)

6.418E-05

0.793 (0.623-0.874)

2p25.2

rs4669394

0.736

1.038 (0.837-1.286)

6.693E-03

0.763 (0.627-0.928)

2p24.1

rs1554267

0.175

0.906 (0.785-1.045)

0.021

1.123 (1.018-1.240)

3p21.31

rs8180040

0.106

0.887 (0.767-1.026)

2.163E-06

0-784 (0-709-0-867)

3q12-q13

rs6438550

0.944

1.012 (0.731-1.400)

4.843E-03

0.723 (0.576-0.906)

5q35.1

rs11740081

0.508

0.935 (0.764-1.142)

4.772E-04

0.783 (0.683-0.898)

6q16.1

rs12213685

0.875

0.987 (0.842-1.157)

6.627E-03

1.220 (1.058-1.407)

6q16.1

rs4538713*

0.939

0.992 (0.804-1.224)

6.282E-04

0.702 (0.627-0.837)

6q23.1

rs12199765

0.231

1.108 (0.93-1.309)

2.693E-05

1.281 (1.141-1.438)

8p12

rs11996339

0.690

0.971 (0.842-1.120)

6.985E-05

0.817 (02739-0.903)

8p12

rs11987193

0.039

0.847 (0.724-0.992)

6.985E-05

0.786 (0.705-0.878)

8p12

rs12548021

0.234

1.095 (0.943-1.271)

2.587E-06

1.28 (1.155-1.418)

8q13.3

rs17788534

0.471

1.073 (0.885-1.301)

8.040E-04

1.249 (1.097-1.422)

8q22.1

rs3104964

0.081

1.139 (0.984-1.317)

4.239E-06

1.265 (1.144-1.398)

10p15.1

rs7074607

0.174

0.867 (0.705-1.065)

0.090

1.131 (0.981-1.305)

10q23.31

rs7087402

NA

NA

NA

NA

12q24.31

rs568489

0.701

1.022 (0.916-1.139)

1.197E-03

1.178 (1.067-1.300)

12q24.31

rs2686555

0.913

1.006 (0.903-1.121)

3.619E-03

1.158 (1.049-1.278)

13q32.3

rs17196583

0.270

0.903 (0.752-1.083)

0.0455

1.136 (1.003-1.288)

14q31.3

rs2057115

0.030

0.791 (0.639-0.977)

0.395

1.065 (0.921-1.231)

14q31.3

rs7148493

0.024

0.843 (0.727-0.977)

0.308

1.054 (0.923-1.165)

14q32.12

rs8177528

0.423

1.056 (0.910-1.225)

1.163E-03

1.183 (1.069-1.309)

15q21.3

rs4644804

0.528

1.037 (0.927-1.159)

0.011

1.139 (1.030-1.259)

15q25.3

rs16941001

0.484

1.067 (0.891-1.277)

5.457E-04

1.351 (1.139-1.603)

15q25.3

rs16941002*

0.560

1.055 (0.880-1.265)

0.127

1.143 (0.952-1.345)

17p13.2

rs16954697

0.280

1.119 (0.913-1.372)

3.168E-04

1.301 (1.127-1.501)

17p12

rs9898623

0.449

0.926 (0.757-1.131)

1.526E-03

0.734 (0.607-0.889)

18p11.22

rs10502376

0.986

0.973 (0.842-1.125)

0.011

0.880 (0.797-0.971)

18q21.2

rs2958182

0.714

1.001 (0.861-1.164)

1.831E-03

1.181 (1.064-1.311)

22q12.3

rs956119

0.369

0.897 (0.708-1.137)

5.911E-03

0.785 (0.660-0.933)

22q12.3

rs17725348*

0.273

0.875 (0.690-1.110)

3.976E-04

0.702 (0.629-0.895)

  1. *Denotes imputed SNPs; NA: not available.
  2. P-values and ORs for the SNPs genotyped in Phase II. All genomic positions correspond to NCBI36/hg18.
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us